
Nextcure (NXTC) Stock Forecast & Price Target
Nextcure (NXTC) Analyst Ratings
Bulls say
NextCure Inc. has secured global rights to the immunotherapy SIM0505 outside of Greater China, with a potential value of up to $745 million in upfront and milestone payments, supplemented by tiered royalties that could reach double-digit percentages on net sales. The company is experiencing positive developments in its drug candidates, particularly in the anti-tumor applications of its ADC programs, with preclinical data demonstrating strong anti-tumor activity and a favorable safety profile. Furthermore, the ongoing clinical trials, including a Phase I study for SIM0505 in the U.S., highlight NextCure's commitment to advancing its innovative cancer therapies, adding to the overall positive outlook for the company's financial prospects.
Bears say
NextCure Inc is experiencing a significant downward adjustment in its projected enterprise value, reducing it from $75 million to $37.5 million, which is indicative of overall weakening market sentiment. The reduction of the price target from $36 to $15 reflects concerns regarding the viability and clinical success of its therapeutic candidates, especially given the inherent risks associated with clinical trials in biopharmaceuticals. Additionally, with the speculative nature of its drug pipeline and the possibility of failure in clinical trials, there are heightened uncertainties regarding the realization of potential revenues in the near future.
This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.
Nextcure (NXTC) Analyst Forecast & Price Prediction
Start investing in Nextcure (NXTC)
Order type
Buy in
Order amount
Est. shares
0 shares